Trauma Clinical Trial
Official title:
A Phase 1, Single Ascending Dose, Double Blind, Placebo Controlled Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1) or Trauma Patients(Part 2)
THIS IS THE SECOND PART OF A 2-PART STUDY. The purpose of the first part of this study was to
determine the safety and tolerability of ascending doses of valproic acid (also known as
Depacon) administered as intravenous infusion (IV) in doses ranging from 15 mg/kg to 250
mg/kg in healthy subjects.
ID: VPA-C-002
The second part of the study will also be to determine the safety and tolerability of single
ascending doses of valproic acid administered as IV in trauma subjects with hemorrhagic
shock.
THIS IS THE SECOND PART OF A 2-PART STUDY. Part 1 of the study will be a single center study
intended to assess the safety and tolerability of valproic acid dosages at 15 mg/kg, 30
mg/kg, 60 mg/kg, 90 mg/kg, 120 mg/kg, 150 mg/kg 180 mg/kg, 210 mg/kg and 250 mg/kg. Up to 72
healthy subjects (9 dose groups of 8 subjects) will receive single doses of valproic acid or
placebo via a 60-min IV infusion in a ratio of 3:1 active drug: placebo. ID: VPA-C-002
Part 2 of the study will be a multi-center, double blind, placebo-controlled study in trauma
patients with hemorrhagic shock. The patients will be able to consent themselves, or if
unable due to injuries, a Legally Authorized Representative will consent for them. Up to 12
patients (2 dose groups of 6 patients) will receive single doses of valproic acid or placebo
via a 60-min IV infusion in a ratio of 2:1 active drug : placebo. The dose levels in Part 2
will be the two highest doses that are demonstrated to have acceptable safety profile based
on the review of safety data from Part 1 (130mg/kg and 140mg/kg).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04848376 -
Post-Market Clinical Follow-up Study of A-SPINE's Products
|
||
Terminated |
NCT03781817 -
Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures
|
Phase 4 | |
Completed |
NCT04342416 -
Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women
|
N/A | |
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Completed |
NCT04356963 -
Adjunct VR Pain Management in Acute Brain Injury
|
N/A | |
Completed |
NCT05669313 -
The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
|
||
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Recruiting |
NCT04725721 -
Testing FIRST in Youth Outpatient Psychotherapy
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT03696563 -
FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS
|
N/A | |
Withdrawn |
NCT03249129 -
Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
|
||
Completed |
NCT02240732 -
Surgical Tourniquets and Cerebral Emboli
|
N/A | |
Completed |
NCT02227979 -
Effects of PURPLE Cry Intervention
|
N/A | |
Withdrawn |
NCT01169025 -
Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients
|
N/A | |
Recruiting |
NCT01812941 -
Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients
|
N/A | |
Completed |
NCT01475344 -
Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)
|
Phase 1/Phase 2 | |
Completed |
NCT03112304 -
Child STEPS for Youth Mental Health in Maine Sustainability
|
N/A | |
Completed |
NCT01201863 -
Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy
|
Phase 4 | |
Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A |